Zydus Lifesciences Limited — Updates, 11-04-2025: Press Release

Zydus Lifesciences Limited has received final approval from the USFDA for the production of Jaythari® (Deflazacort) Tablets in 6 mg, 18 mg, 30 mg, and 36 mg dosages, which are indicated for treating Duchenne muscular dystrophy (DMD) in patients aged 5 and older. The manufacturing will take place at Doppel Farmaceutici S.r.l., Italy. This approval marks a significant addition to Zydus's portfolio as the company now holds a total of 424 approvals and has filed 492 ANDAs since the beginning of its filing process in FY 2003-04. This approval enhances Zydus's competitive position in the market and represents a positive opportunity for growth, particularly within the niche segment of DMD treatments. Shareholders should monitor this development closely, as it could strengthen the company's revenue streams in the upcoming quarters.